AP2014007836A0 - Apoptosis signal-regulating kinase inhibitor - Google Patents
Apoptosis signal-regulating kinase inhibitorInfo
- Publication number
- AP2014007836A0 AP2014007836A0 AP2014007836A AP2014007836A AP2014007836A0 AP 2014007836 A0 AP2014007836 A0 AP 2014007836A0 AP 2014007836 A AP2014007836 A AP 2014007836A AP 2014007836 A AP2014007836 A AP 2014007836A AP 2014007836 A0 AP2014007836 A0 AP 2014007836A0
- Authority
- AP
- ARIPO
- Prior art keywords
- kinase inhibitor
- apoptosis signal
- regulating kinase
- regulating
- apoptosis
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591710P | 2012-01-27 | 2012-01-27 | |
| PCT/US2013/022997 WO2013112741A1 (en) | 2012-01-27 | 2013-01-24 | Apoptosis signal-regulating kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2014007836A0 true AP2014007836A0 (en) | 2014-07-31 |
Family
ID=47684038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2014007836A AP2014007836A0 (en) | 2012-01-27 | 2013-01-24 | Apoptosis signal-regulating kinase inhibitor |
Country Status (39)
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| ES2617339T3 (es) | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2015081127A2 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| WO2015109286A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
| US20150342943A1 (en) * | 2014-06-03 | 2015-12-03 | Gilead Sciences, Inc. | Methods of treating liver disease |
| TW201618781A (zh) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
| JP2017528471A (ja) * | 2014-09-24 | 2017-09-28 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置する方法 |
| WO2016106384A1 (en) * | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| MA41252A (fr) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| RS56787B1 (sr) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina |
| SMT201900244T1 (it) | 2015-07-06 | 2019-05-10 | Gilead Sciences Inc | Modulatori di cot e metodi per il loro uso |
| TW201725044A (zh) | 2015-10-01 | 2017-07-16 | 基利科學股份有限公司 | 用於治療癌症之btk抑制劑及查核點抑制劑之組合 |
| AU2016329075A1 (en) * | 2015-10-02 | 2018-04-26 | Gilead Sciences, Inc. | Combinations of the BTK inhibitor GS-4059 with inhibitors selected from a JAK, ASK1, BRD and/or MMP9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| US10316049B2 (en) | 2015-12-17 | 2019-06-11 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| EP3440113A1 (en) | 2016-04-08 | 2019-02-13 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| US10059769B2 (en) | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
| WO2018026835A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CA3035346A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| US20180133203A1 (en) | 2016-11-11 | 2018-05-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| WO2018097977A1 (en) | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| ES2870524T3 (es) * | 2017-01-22 | 2021-10-27 | Fujian Cosunter Pharmaceutical Co Ltd | Derivado de piridina como inhibidor de ASK1, y método de preparación y uso del mismo |
| US10584169B2 (en) | 2017-01-24 | 2020-03-10 | I-Mab Biopharma Us Limited | Anti-CD73 antibodies and uses thereof |
| KR102362646B1 (ko) | 2017-02-24 | 2022-02-11 | 길리애드 사이언시즈, 인코포레이티드 | 브루톤의 티로신 키나제의 억제제 |
| EP3585789A1 (en) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2018157277A1 (en) * | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| JP7211959B2 (ja) * | 2017-03-03 | 2023-01-24 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | アミド類誘導体阻害剤及びその製造方法と使用 |
| JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
| KR20190126921A (ko) | 2017-03-28 | 2019-11-12 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하는 방법 |
| CA3059883A1 (en) | 2017-04-12 | 2018-10-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018209354A1 (en) | 2017-05-12 | 2018-11-15 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218044A2 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10495648B2 (en) | 2017-06-13 | 2019-12-03 | Gilead Sciences, Inc. | Methods of treating liver fibrosis |
| TW201908306A (zh) * | 2017-07-18 | 2019-03-01 | 大陸商南京聖和藥業股份有限公司 | 作為ask抑制劑的雜環化合物及其應用 |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN109456308B (zh) * | 2017-09-06 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
| US10370352B2 (en) | 2017-09-07 | 2019-08-06 | Eli Lilly And Company | Cyclobutyl-imidazolidinone compounds |
| WO2019047094A1 (en) * | 2017-09-07 | 2019-03-14 | Eli Lilly And Company | CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS |
| WO2019047161A1 (en) * | 2017-09-08 | 2019-03-14 | Eli Lilly And Company | IMIDAZOLIDINE COMPOUNDS |
| EP3678662A4 (en) | 2017-09-08 | 2021-09-01 | Fronthera U.S. Pharmaceuticals LLC | APOPTOSIS SIGNAL REGULATION KINASE INHIBITORS AND THEIR USES |
| CN109232538B (zh) * | 2017-10-12 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
| CN107793400B (zh) * | 2017-10-31 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用 |
| EP3710599B1 (en) | 2017-11-13 | 2024-07-17 | Gilead Sciences, Inc. | Method for staging liver fibrosis in nash patients |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| EP3735404B1 (en) | 2018-01-02 | 2023-11-29 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| PE20210640A1 (es) | 2018-02-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| CN110294742B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 并环类ask1抑制剂及其应用 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| WO2019200267A1 (en) | 2018-04-12 | 2019-10-17 | Terns, Inc. | Tricyclic ask1 inhibitors |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP3787621B1 (en) | 2018-05-02 | 2024-12-18 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| EP3814272A4 (en) | 2018-05-11 | 2022-03-02 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| MY198871A (en) | 2018-05-14 | 2023-10-02 | Gilead Sciences Inc | Mcl-1 inhibitors |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
| KR102625712B1 (ko) | 2018-07-13 | 2024-01-19 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| JP7096460B2 (ja) * | 2018-07-20 | 2022-07-06 | 福建▲広▼生中霖生物科技有限公司 | Ａｓｋ１阻害剤としての結晶形、その製造方法及び利用 |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| KR102298546B1 (ko) | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| CN111170995A (zh) * | 2018-11-09 | 2020-05-19 | 山东轩竹医药科技有限公司 | Ask1抑制剂及其应用 |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN109608441A (zh) * | 2018-12-26 | 2019-04-12 | 都创(上海)医药科技有限公司 | 一种ask1抑制剂的合成工艺 |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| CN109813915A (zh) * | 2019-02-15 | 2019-05-28 | 浠思（上海）生物技术有限公司 | 利用htrf一步法筛选激酶抑制剂的方法 |
| CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR20210136081A (ko) | 2019-03-11 | 2021-11-16 | 길리애드 사이언시즈, 인코포레이티드 | 화합물의 제제 및 그의 용도 |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| TWI855100B (zh) * | 2019-06-26 | 2024-09-11 | 印度商人類製藥有限公司 | 新型細胞凋亡訊號調節激酶1抑制劑 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| JP7431961B2 (ja) | 2019-11-15 | 2024-02-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用 |
| CN111018831B (zh) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | 细胞凋亡信号调节激酶抑制剂及其应用 |
| US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
| KR20220131918A (ko) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | 다이아실글리세롤 키나제 조절 화합물 |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| CA3175541A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| US11845737B2 (en) | 2020-04-02 | 2023-12-19 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
| AU2021264550A1 (en) | 2020-05-01 | 2022-11-17 | Gilead Sciences, Inc. | CD73 inhibiting 2,4-dioxopyrimidine compounds |
| KR20230019880A (ko) | 2020-06-03 | 2023-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| CN113831323B (zh) * | 2020-06-24 | 2025-08-29 | 武汉人福创新药物研发中心有限公司 | 芳杂环酰胺类化合物及其用途 |
| CN111808079A (zh) * | 2020-08-05 | 2020-10-23 | 中国药科大学 | 吲哚类ask1小分子抑制剂及其制备方法和应用 |
| CN114470217B (zh) * | 2020-11-24 | 2023-06-20 | 深圳微芯生物科技股份有限公司 | 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物 |
| US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| WO2022212194A1 (en) | 2021-03-29 | 2022-10-06 | Gilead Sciences, Inc. | Khk inhibitors |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CN114246866B (zh) * | 2021-04-28 | 2023-09-12 | 深圳微芯生物科技股份有限公司 | 用于治疗慢性肾病的药物及其用途 |
| TWI818538B (zh) | 2021-05-11 | 2023-10-11 | 美商基利科學股份有限公司 | Ｌｐａ受體拮抗劑及其用途 |
| CN117295724A (zh) | 2021-05-13 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
| TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| PE20242071A1 (es) | 2021-06-23 | 2024-10-18 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa |
| AU2022297367B2 (en) | 2021-06-23 | 2025-04-10 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences Inc | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| CN119031937A (zh) | 2022-03-24 | 2024-11-26 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的联合疗法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| JP2025522762A (ja) | 2022-07-01 | 2025-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN115844887B (zh) * | 2022-12-28 | 2023-09-08 | 中国人民解放军空军军医大学 | Selonsertib在制备治疗癌症的药物中的用途 |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024259556A1 (en) | 2023-04-21 | 2025-10-23 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024236595A1 (en) * | 2023-05-18 | 2024-11-21 | Council Of Scientific And Industrial Research | Protacs for ask1 protein degradation: preparation and use thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| TW202519517A (zh) | 2023-07-26 | 2025-05-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159731A (en) | 1997-02-12 | 2000-12-12 | Massachusetts Institute Of Technology | Daxx, a Fas-binding protein that activates JNK and apoptosis |
| US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| IL141984A0 (en) | 1999-03-19 | 2002-03-10 | Aventis Pharm Prod Inc | Akt nucleic acids, polypeptides, and uses thereof |
| WO2001095410A1 (en) * | 2000-06-07 | 2001-12-13 | Andelman Marc D | Fluid and electrical connected flow-through electrochemical cells, system and method |
| US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| US20070167386A1 (en) | 2003-07-28 | 2007-07-19 | Osaka Industrial Promotion Organization | Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same |
| WO2006036941A2 (en) | 2004-09-27 | 2006-04-06 | Kosan Biosciences Incorporated | Specific kinase inhibitors |
| CA2586870A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| EP1677113A1 (en) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Method for the identification of protein-protein interactions in disease related protein networks |
| US20070276050A1 (en) | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
| WO2008016131A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| WO2008042867A2 (en) | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| AU2007333106A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| US8104727B2 (en) | 2007-03-12 | 2012-01-31 | Denis Joanisse | Adjustable article support |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| AU2008291075A1 (en) * | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
| WO2009123986A1 (en) | 2008-03-31 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| US8178555B2 (en) | 2008-06-24 | 2012-05-15 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| WO2010045470A2 (en) | 2008-10-15 | 2010-04-22 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders |
| US20110294693A1 (en) | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| EP2411516A1 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| ES2445917T3 (es) | 2010-02-03 | 2014-03-06 | Takeda Pharmaceutical Company Limited | Inhibidores de quinasa 1 reguladora de la señal de apoptosis |
| EP2534145A4 (en) | 2010-02-08 | 2013-09-11 | Kinagen Inc | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE |
| JP6065183B2 (ja) | 2010-03-24 | 2017-01-25 | アミテック セラピューティック ソリューションズ，インク． | キナーゼ阻害に役立つ複素環式化合物 |
| KR101759759B1 (ko) * | 2010-07-02 | 2017-07-19 | 길리애드 사이언시즈, 인코포레이티드 | 세포자멸사 신호-조절 키나아제 저해제 |
| US20130236441A1 (en) | 2010-11-18 | 2013-09-12 | University Of Delaware | Methods of treating and preventing thrombotic diseases using ask1 inhibitors |
| ES2617339T3 (es) | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| EP2678448A4 (en) | 2011-02-22 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | CIRCULATING BIOMARKERS |
| CN103782174A (zh) | 2011-06-07 | 2014-05-07 | 卡里斯生命科学卢森堡控股有限责任公司 | 用于癌症的循环生物标志物 |
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| US8924765B2 (en) | 2011-07-03 | 2014-12-30 | Ambiq Micro, Inc. | Method and apparatus for low jitter distributed clock calibration |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| WO2016106384A1 (en) | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
-
2013
- 2013-01-11 UY UY0001034573A patent/UY34573A/es not_active Application Discontinuation
- 2013-01-24 HU HUE13703675A patent/HUE028641T2/en unknown
- 2013-01-24 JP JP2014554828A patent/JP5770950B2/ja active Active
- 2013-01-24 EP EP13703675.2A patent/EP2807151B1/en active Active
- 2013-01-24 PE PE2014001153A patent/PE20141822A1/es active IP Right Grant
- 2013-01-24 AU AU2013201586A patent/AU2013201586C1/en active Active
- 2013-01-24 SG SG11201404348UA patent/SG11201404348UA/en unknown
- 2013-01-24 KR KR1020187037026A patent/KR20190000898A/ko not_active Ceased
- 2013-01-24 KR KR1020177032774A patent/KR20170128622A/ko not_active Ceased
- 2013-01-24 PL PL13703675T patent/PL2807151T3/pl unknown
- 2013-01-24 CN CN201811215092.XA patent/CN109438418B/zh active Active
- 2013-01-24 BR BR112014018355-4A patent/BR112014018355B1/pt active IP Right Grant
- 2013-01-24 SI SI201330109A patent/SI2807151T1/sl unknown
- 2013-01-24 ME MEP-2016-5A patent/ME02322B/me unknown
- 2013-01-24 UA UAA201407926A patent/UA112098C2/uk unknown
- 2013-01-24 HR HRP20151399TT patent/HRP20151399T1/hr unknown
- 2013-01-24 US US13/748,901 patent/US8742126B2/en active Active
- 2013-01-24 MX MX2014009075A patent/MX2014009075A/es active IP Right Grant
- 2013-01-24 MD MDA20140082A patent/MD4601B1/ro not_active IP Right Cessation
- 2013-01-24 EA EA201491283A patent/EA024746B1/ru unknown
- 2013-01-24 PT PT137036752T patent/PT2807151E/pt unknown
- 2013-01-24 WO PCT/US2013/022997 patent/WO2013112741A1/en not_active Ceased
- 2013-01-24 CA CA3026738A patent/CA3026738C/en active Active
- 2013-01-24 RS RS20160019A patent/RS54492B1/sr unknown
- 2013-01-24 KR KR1020177003620A patent/KR101799739B1/ko active Active
- 2013-01-24 CN CN201380006957.0A patent/CN104080771B/zh active Active
- 2013-01-24 KR KR1020157036387A patent/KR101707764B1/ko active Active
- 2013-01-24 KR KR1020147023533A patent/KR101582065B1/ko active Active
- 2013-01-24 CA CA3026700A patent/CA3026700C/en active Active
- 2013-01-24 MX MX2015009422A patent/MX365954B/es unknown
- 2013-01-24 AP AP2014007836A patent/AP2014007836A0/xx unknown
- 2013-01-24 ES ES13703675.2T patent/ES2558203T3/es active Active
- 2013-01-24 DK DK13703675.2T patent/DK2807151T3/en active
- 2013-01-24 CA CA2862030A patent/CA2862030C/en active Active
- 2013-01-24 NZ NZ739339A patent/NZ739339A/en unknown
- 2013-01-25 TW TW102102991A patent/TWI487523B/zh active
- 2013-01-25 AR ARP130100241A patent/AR089818A1/es active IP Right Grant
- 2013-01-25 TW TW103125752A patent/TWI561514B/zh active
- 2013-01-25 TW TW105128669A patent/TWI634890B/zh active
- 2013-01-25 TW TW107127139A patent/TW201916877A/zh unknown
-
2014
- 2014-04-16 US US14/254,359 patent/US9333197B2/en active Active
- 2014-04-16 US US14/254,342 patent/US9254284B2/en active Active
- 2014-07-10 IL IL233598A patent/IL233598A/en active IP Right Grant
- 2014-07-11 MA MA37202A patent/MA35861B1/fr unknown
- 2014-07-17 ZA ZA2014/05260A patent/ZA201405260B/en unknown
- 2014-07-22 IN IN6174DEN2014 patent/IN2014DN06174A/en unknown
- 2014-07-25 PH PH12014501697A patent/PH12014501697A1/en unknown
- 2014-07-25 CL CL2014001988A patent/CL2014001988A1/es unknown
- 2014-07-25 MX MX2019007348A patent/MX2019007348A/es unknown
- 2014-08-26 CO CO14186994A patent/CO7061073A2/es unknown
- 2014-08-29 CR CR20140405A patent/CR20140405A/es unknown
-
2015
- 2015-06-10 IL IL239311A patent/IL239311B/en active IP Right Grant
-
2016
- 2016-02-15 SM SM201600047T patent/SMT201600047B/it unknown
- 2016-02-16 CY CY20161100129T patent/CY1117201T1/el unknown
- 2016-04-27 US US15/140,204 patent/US9750730B2/en active Active
-
2017
- 2017-04-19 US US15/491,689 patent/US9873682B2/en active Active
- 2017-12-13 US US15/840,429 patent/US20180099950A1/en not_active Abandoned
-
2018
- 2018-03-07 IL IL257965A patent/IL257965A/en unknown
-
2019
- 2019-01-11 US US16/246,199 patent/US10508100B2/en active Active
- 2019-11-19 AR ARP190103385A patent/AR117113A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257965A (en) | Apoptosis signal-regulated kinase inhibitor | |
| IL247405A0 (en) | Apoptosis signal-regulating kinase inhibitors | |
| IL255799B (en) | Converted pyridine-2-carboxamide compounds as inhibitors of apoptosis signal-regulated kinase | |
| IL245807A0 (en) | Apoptosis signal-modulating kinase inhibitors | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| PT2892889T (pt) | Compostos inibidores | |
| PT2531501E (pt) | Inibidores da cinase de regulação do sinal de apoptose 1 | |
| EP2900668A4 (en) | INHIBITORS OF MULTIPLE KINASE PATHWAYS | |
| GB201211310D0 (en) | CSF-1R kinase inhibitors | |
| PL2634185T3 (pl) | Inhibitory kinazy TYK2 | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| EP2903970A4 (en) | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| EP2900243A4 (en) | BICYCLIC OXA LACTAM KINASE HEMMER | |
| GB201211019D0 (en) | Inhibitor compounds |